TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06504953

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaires on contraception and sports activities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaires on contraception and sports activities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaires on contraception and sports activities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beighton test
Description: A popular screening technique for hypermobility. It consists of a nine-point scale requiring the performance of five maneuvers, four passive bilateral and one active unilateral.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beighton test
Description: A popular screening technique for hypermobility. It consists of a nine-point scale requiring the performance of five maneuvers, four passive bilateral and one active unilateral.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beighton test
Description: A popular screening technique for hypermobility. It consists of a nine-point scale requiring the performance of five maneuvers, four passive bilateral and one active unilateral.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lachman Test
Description: To perform this test, place your patient in a supine position and bring your patient's test leg to 30 degrees of flexion. Fix the femur with the other hand. Put the tibia in slight external rotation, then try to translate it forwards.~This test is positive if you feel a soft or limp end or if the anterior part.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lachman Test
Description: To perform this test, place your patient in a supine position and bring your patient's test leg to 30 degrees of flexion. Fix the femur with the other hand. Put the tibia in slight external rotation, then try to translate it forwards.~This test is positive if you feel a soft or limp end or if the anterior part.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lachman Test
Description: To perform this test, place your patient in a supine position and bring your patient's test leg to 30 degrees of flexion. Fix the femur with the other hand. Put the tibia in slight external rotation, then try to translate it forwards.~This test is positive if you feel a soft or limp end or if the anterior part.
Study: NCT06506643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc-64 Aspartate
Description: KLS-1 drug substance is Zinc Aspartate enriched with isotope Zinc-64 to 99.2% mass fraction of total Zinc. KLS-1 investigational medicinal product (IMP) is formulated as a solution, containing 25.64 mg of drug substance in 1 ml and inactive ingredients (water for injections, USP, EuPh).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc-64 Aspartate
Description: KLS-1 drug substance is Zinc Aspartate enriched with isotope Zinc-64 to 99.2% mass fraction of total Zinc. KLS-1 investigational medicinal product (IMP) is formulated as a solution, containing 25.64 mg of drug substance in 1 ml and inactive ingredients (water for injections, USP, EuPh).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc-64 Aspartate
Description: KLS-1 drug substance is Zinc Aspartate enriched with isotope Zinc-64 to 99.2% mass fraction of total Zinc. KLS-1 investigational medicinal product (IMP) is formulated as a solution, containing 25.64 mg of drug substance in 1 ml and inactive ingredients (water for injections, USP, EuPh).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc-64 Aspartate
Description: KLS-1 drug substance is Zinc Aspartate enriched with isotope Zinc-64 to 99.2% mass fraction of total Zinc. KLS-1 investigational medicinal product (IMP) is formulated as a solution, containing 25.64 mg of drug substance in 1 ml and inactive ingredients (water for injections, USP, EuPh).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc-64 Aspartate
Description: KLS-1 drug substance is Zinc Aspartate enriched with isotope Zinc-64 to 99.2% mass fraction of total Zinc. KLS-1 investigational medicinal product (IMP) is formulated as a solution, containing 25.64 mg of drug substance in 1 ml and inactive ingredients (water for injections, USP, EuPh).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc-64 Aspartate
Description: KLS-1 drug substance is Zinc Aspartate enriched with isotope Zinc-64 to 99.2% mass fraction of total Zinc. KLS-1 investigational medicinal product (IMP) is formulated as a solution, containing 25.64 mg of drug substance in 1 ml and inactive ingredients (water for injections, USP, EuPh).
Study: NCT06271668

Intervention type: OTHER
Intervention: Naloxone Co-prescribing Clinical Decision Support (CDS)
Description: Clinical decision support in the form of an EHR-integrated, provider facing alert suggesting (a) the opioid medication order is considered high risk for overdose and (b) to nudge providers to add a naloxone prescription to the opioid prescription to mitigate risk in the event of an overdose.
Study: NCT05525572

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave Therapy (SWT)
Description: Shockwave Therapy (SWT):~720 shocks will be administered administered in every session to each treated region (left and right corpora cavernosa and crura). Each session will last approximately 20 minutes. A total of 3600 shocks will be administered over 5 weekly sessions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Platelet-Rich Plasma (PRP)
Description: Autologous Platelet Rich Plasma (PRP):~5 mL PRP will be administered via intra-cavernous penile injection with a 30 ± 7 day treatment interval.
Study: NCT06191328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiglitazar sodium
Description: In patients with type 2 diabetes mellitus (T2DM), on the basis of one or two oral hypoglycemic agents combination with Chiglitazar sodium.
Study: NCT06648564

Intervention type: PROCEDURE
Intervention: Bone regenerative surgery with a bone graft substitute and a resorbable membrane
Description: Dental implants with a diagnosis peri-implantitis were treated with regenerative surgery.
Study: NCT04782453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ToQuit, a technology delivered tobacco cessation intervention
Description: The intervention messages will consist of specific content areas derived from the formative research of the study. Some of the components of the intervention include~* Psychoeducation about consequences of tobacco use and benefits of quitting;~* goal setting;~* managing goals and self-monitoring of behavior;~* avoidance strategies;~* self-awareness and reflection messages;~* social and pharmacological support, and help-seeking;~* identifying and managing cravings;~* relapse prevention strategies.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tobacco quitting helplines
Description: Participants from the control group will be sent the details of other functional tobacco helplines in India.
Study: NCT05468242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant chemo-immunotherapy
Description: The neoadjuvant chemo-immunotherapy before radiotherapy comprised of chemotherapy plus Tislelizumab \[200 mg, once every 3 weeks (Q3W)\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemo-immunotherapy
Description: The neoadjuvant chemo-immunotherapy before radiotherapy comprised of chemotherapy plus Tislelizumab \[200 mg, once every 3 weeks (Q3W)\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: The Bevacizumab was administrated concurrently with neoadjuvant chemo-immunotherapy (7.5mg/kg) once every 3 weeks (Q3W).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Definitive radiotherapy to the thoracic lesions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Definitive radiotherapy to the thoracic lesions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: Tislelizumab consolidation (200 mg) is performed once every 3 weeks after the neoadjuvant therapy and concurrent chemo-radiotherapy, and will continue on a Q3W schedule for a maximum duration of 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab consolidation (200 mg) is performed once every 3 weeks after the neoadjuvant therapy and concurrent chemo-radiotherapy, and will continue on a Q3W schedule for a maximum duration of 12 months.
Study: NCT05742360

Intervention type: DEVICE
Intervention: CPAP therapy
Description: CPAP treatment of obstructive sleep apnea with the excessively sleepy symptom subtype
Study: NCT05098912

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual acupuncture
Description: Manual acupuncture using filiform needle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thread embedding acupuncture
Description: Thread Embedding acupuncture using Polydioxanone thread
Study: NCT05523193

Intervention type: OTHER
Intervention: Formal treatment model
Description: Formal treatment model , no further surgery or minimally invasive treatment was performed
Study: NCT06339164

Intervention type: OTHER
Intervention: skills and learning quality in breech delivery
Description: evaluation of different skill retention and learning quality after different learning methods

Intervention type: OTHER
Intervention: skills and learning quality in breech delivery
Description: evaluation of different skill retention and learning quality after different learning methods
Study: NCT05303064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLZ/SAM
Description: OLZ/SAM refers to the fixed dose combination of olanzapine and samidorphan. The starting dose of olanzapine will be 2.5 mg/day or 5 mg/day at the discretion of the Investigator with a maximum daily dose of 20mg/day. The starting dose of samidorphan will be 5 or 10 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: The starting dose of olanzapine will be 2.5 mg/day or 5 mg/day at the discretion of the Investigator with a maximum daily dose of 20mg/day
Study: NCT04550975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advanced Cognitive Stimulation Therapy
Description: An adapted version of Cognitive Stimulation Therapy for people with moderate to severe dementia.
Study: NCT05040672

Intervention type: BEHAVIORAL
Intervention: questionare online application
Description: questionare online application
Study: NCT04805580

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: unilateral intrathecal block
Description: Quadratus lunborum block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: unilateral intrathecal block
Description: Quadratus lunborum block
Study: NCT06440356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laser therapy
Description: low level laser therapy applied
Study: NCT05556161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General Practitioners and Diabetes Specialists Co-management
Description: Self-monitoring of blood glucose: Participants will monitor blood glucose with a a free intelligent home blood glucose meter. Then, the intelligent blood glucose meter will upload data to the platform.~Glycosylated hemoglobin check: Participants will receive HbA1c test once every three months.~Cooperative General Practitioner-Specialist Management: Based on the remote monitoring of blood glucose and HbA1c tests, general practitioners and specialists will jointly carry out management measures including health education, medication adjustment, outpatient consultation, referral, case discussion, etc. for participants.
Study: NCT05622877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qushi Formula
Description: Qushi Formula are decoction granules composed 8 traditional Chinese medicines, such as poria cocos, Macrocephalae Rhizoma, Polyporus, cassia twig, dried ginger and licorice, Etc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zhu's Wenban Formula
Description: Zhu's Wenban granules are decoction granules composed of leech, panax notoginseng, Atractylodes Lancea and rhizome

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo was composed of dextrin, powdered sugar, starch, and liquid caramel in the same color as the other two groups.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Basic treatment
Description: Basic diseases except hyperlipidemia were treated in accordance with the 2014 Chinese Guidelines for Secondary Prevention of Ischemic Stroke/Transient Ischemic Attack. Basic treatment includes conventional treatment such as comprehensive prevention and treatment (actively controlling basic diseases such as hypertension and diabetes and suggesting a good lifestyle), drug therapy (anti-inflammatory, lipid-regulating, anti-platelet aggregation, calcium channel blockers) and so on according to individual conditions of patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic treatment
Description: Basic diseases except hyperlipidemia were treated in accordance with the 2014 Chinese Guidelines for Secondary Prevention of Ischemic Stroke/Transient Ischemic Attack. Basic treatment includes conventional treatment such as comprehensive prevention and treatment (actively controlling basic diseases such as hypertension and diabetes and suggesting a good lifestyle), drug therapy (anti-inflammatory, lipid-regulating, anti-platelet aggregation, calcium channel blockers) and so on according to individual conditions of patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic treatment
Description: Basic diseases except hyperlipidemia were treated in accordance with the 2014 Chinese Guidelines for Secondary Prevention of Ischemic Stroke/Transient Ischemic Attack. Basic treatment includes conventional treatment such as comprehensive prevention and treatment (actively controlling basic diseases such as hypertension and diabetes and suggesting a good lifestyle), drug therapy (anti-inflammatory, lipid-regulating, anti-platelet aggregation, calcium channel blockers) and so on according to individual conditions of patients.
Study: NCT06174298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor (Filgrastim)
Description: Intervention Group Fresh Embryo Transfers: On day 5 or 6 of culture, viable embryos will be transferred into a center-well dish containing 1 mL of embryo transfer media supplemented with GCSF. The embryos will be cultured in this medium for approximately 3 hours before the embryo transfer (ET) procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician.~Intervention Group Frozen Embryo Transfers: Cryopreserved embryos will be thawed according to the Kitazato thawing protocol and will be subsequently transferred to a center-well dish containing 1 mL of embryo transfer media supplemented with GCSF. The embryos will be cultured in this medium for approximately 3 hours before the ET procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Embryo Transfer Media
Description: Control Group Fresh Embryo Transfers: On day 5 or 6 of culture, viable embryos will be transferred into a center-well dish containing 1 mL of embryo transfer media. The embryos will be cultured in this medium for approximately 3 hours before the embryo transfer (ET) procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician.~Control Group Frozen Embryo Transfers: Cryopreserved embryos will be thawed according to the Kitazato thawing protocol and will be subsequently transferred to a center-well dish containing 1 mL of embryo transfer media. The embryos will be cultured in this medium for approximately 3 hours before the ET procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician.
Study: NCT06028074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIM122
Description: GIM-122 administered IV once every 3 weeks
Study: NCT06310499

Intervention type: OTHER
Intervention: Drowning
Description: Drowning is defined as the process of experiencing respiratory impairment from submersion or immersion in liquid.

Intervention type: OTHER
Intervention: Drowning
Description: Drowning is defined as the process of experiencing respiratory impairment from submersion or immersion in liquid.
Study: NCT05943275

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic sensor
Description: During the right heart catheterization procedure, measurement of hemodynamic pressures by the non-invasive experimental method (Magnetic sensor) and the invasive control method
Study: NCT06493123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Cardiopulmonary Rehabilitation
Description: Conventional cardiopulmonary applications including positioning, chest physiotherapy, in-bed normal joint movement exercises, sitting and walking, posture exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Cardiopulmonary Rehabilitation
Description: Conventional cardiopulmonary applications including positioning, chest physiotherapy, in-bed normal joint movement exercises, sitting and walking, posture exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Cardiopulmonary Rehabilitation
Description: Conventional cardiopulmonary applications including positioning, chest physiotherapy, in-bed normal joint movement exercises, sitting and walking, posture exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bottle P.E.P. (Pozitive Expiratory Pressure)
Description: The device will be built according to the optimal design parameters for a positive expiratory pressure therapy bottle device established by Mestriner et al. According to this~Bottle-P.E.P. device:~* PEP: 10-20 cmH2O~* Inspiration: Expiration Ratio: 1:3-4~* Material Used: Open top plastic bottle, plastic pipe.~Plastic Bottle Specifications:~I. Material-Hard Plastic II. Dimensions-Weight- 40grams; Height- 25cm; Width- 10cm; Perimeter- 20cm III. Water column height- 13cm~Plastic Pipe Properties:~I. Material-Pipette II. Inner Diameter- ≥8mm III. Pipe Length- 30cm IV. Depth in the water column - 10cm; 3 cm above the bottom of the bottle surface.~- The distal end of the tube used in the Bottle P.E.P. will be placed 10 cm below the surface, i.e. 10 cm water column and 3 cm above the bottom of the bottle, and the device will be placed on a table in front of the participant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Mobilization
Description: The Maebashi mobilization protocol will be followed for early mobilization program. According to this protocol, the hemodynamic and respiratory parameters of the patient will be evaluated first and the patient who meets the criteria for the mobilization program will be started to the mobilization program according to the appropriate stage of the 5-stage mobilization protocol.~In Maebashi Mobilization protocol:~Level 1: No mobilization and in-bed passive exercise Level 2: Supported in-bed sitting and in-bed active/assistive-active exercise Level 3: Unassisted sitting on the edge of the bed Level 4: Active transfer to chair Level 5: Standing, stepping in place and supported walking about 10 meters (with support of 2 people)
Study: NCT06078358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: Traditional linear periodization resistance training.
Study: NCT05605717

Intervention type: RADIATION
Intervention: Fibroscan
Description: Liver fibroscan and ultrasonography
Study: NCT06268444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7-day actimetry sleep recording
Description: 7-day actimetry sleep recording

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Determination of environmental pollutants in breast milk
Description: Determination of environmental pollutants in breast milk

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurements of environmental pollutants in indoor air deposited on the bracelet worn by the child
Description: Measurements of environmental pollutants in indoor air deposited on the bracelet worn by the child

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous recording of the child&#39;s temperature for 7 days
Description: Continuous recording of the child\&#39;s temperature for 7 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of a sleep diary for 7 days
Description: Use of a sleep diary for 7 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parental questionnaire of environmental exposure
Description: Parental questionnaire of environmental exposure
Study: NCT06280287

Intervention type: DIAGNOSTIC_TEST
Intervention: FAPI PET
Description: 68Ga-FAPI PET/MR with high-resolution cardiovascular magnetic resonance vessel wall imaging for patients with carotid stenosis; 18FAl-FAPI PET/CT for patients with coronary artery disease

Intervention type: DIAGNOSTIC_TEST
Intervention: FAPI PET
Description: 68Ga-FAPI PET/MR with high-resolution cardiovascular magnetic resonance vessel wall imaging for patients with carotid stenosis; 18FAl-FAPI PET/CT for patients with coronary artery disease
Study: NCT06561230

Intervention type: OTHER
Intervention: Chart review
Description: Patients eligible for prescreening will be identified using structured criteria (e.g., anyone with an appointment in the upcoming 2 months with a relevant provider). All individual charts will be de-identified. De-identified EHRs will then be transferred to Mendel's secure data abstraction platform, where trial eligibility criteria will be abstracted. Patients will be rank-ordered by number of eligibility criteria met, with patients meeting the most eligibility criteria at the top of the queue. The study team will then review eligibility criteria and flag eligible patients.
Study: NCT05711888

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semantic Recognition Procedure
Description: A semantic recognition task is going to be added to administrated FCSRT procedure after immediate and delayed recall phases.
Study: NCT05754684

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural killer cell
Description: Natural killer cells isolated from HLA-haploidentical relative donor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinutuximab beta
Description: Dinutuximab beta iv for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2 sc alternate day for 6 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-Macrophage Colony-Stimulating Factor
Description: Granulocyte-macrophage colony-stimulating factor sc daily till ANC \>2,000/mm3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone po three time daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naxitamab
Description: Naxitamab iv for 4 days (as alternative for dinutuximab)